Document is current

Article History

Received: 25 August 2025

Revised: 1 December 2025

Accepted: 29 December 2025

First Online: 20 January 2026

Competing interests

: IK reports honoraria for talks from AbbVie, AstraZeneca, Lilly, Incyte and for advisory board participation from Janssen-Cilag GmbH (J&J), Lilly and SOBi (partly to institution); training and travel grant from Janssen-Cilag, Roche, SOBi; congress participation fee from Abbvie, Johnson&Johnson, Lilly, SOBi. JCH reports honoraria for talks from BMS, Delcath, Immunocore, MSD, Novartis, Pierre Fabre, Sanofi and Sunpharma and honoraria for advisory board participation from Onkowissen and Sunpharma. UH reports honorarium for talks: Janssen, Pfizer, Alnylam, Akcea, Prothena, Astra Zeneca; financial support of congress participation: Janssen, Prothena, Pfizer; advisory boards: Pfizer, Prothena, Janssen, Alexion; financial sponsoring of Amyloidosis Registry: Janssen. Peter Dreger reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); research support from Riemser (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. The remaining authors declare no competing financial interests.

: The study was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent to data collection and scientific evaluation before admission to alloHCT. Data analysis was approved by the institutional review board (Ethics Committee of the Medical Faculty of Heidelberg University, S-200/2010).